Overall cases of colon and rectal cancer are down, but experts are worried that the proportion of cases is shifting to younger people with more advanced disease.
The burden of colorectal cancer in the United States is shifting to younger adults, and more patients are being diagnosed with later stage disease, according to a concerning new report from the American Cancer Society.
One in 5 new cases of colorectal cancer in the United States occur in people younger than 55 — about twice the rate in 1995, when 11 percent of cases were in this age group. In another alarming shift, 60 percent of patients are being diagnosed with an advanced stage of the disease, up from 52 percent in the mid-2000s.
The reasons behind the trends aren’t fully understood, but the findings suggest that steady progress to reduce the incidence of colon cancer through screening during the past few decades is losing momentum.
“There is a bit of a worrisome trend,” said Paul Oberstein, a medical oncologist at the NYU Langone Perlmutter Cancer Center who was not involved in the study. “Something is clearly different among the young, the under 50 population, that does suggest, although it’s small, that the number of cancers are going up.”
Overall, colorectal cancer is on the decline, largely because more people over 50 are being screened by colonoscopy, which can prevent cancer by detecting and removing premalignant polyps. Recently, the U.S. Preventive Services Task Force recommended lowering the age for colorectal cancer screen to 45.
But the new report “foreshadows less favorable trends ahead,” the study authors wrote, with more patients being diagnosed at younger ages and with more advanced disease. There is also an unexplained shift in the incidence of “left-sided” tumors, suggesting that the biology of the disease could be changing, prompting a need for a new approach in prevention and more research into targeted treatments.
“We know rates are increasing in young people, but it’s alarming to see how rapidly the whole patient population is shifting younger, despite shrinking numbers in the overall population,” Rebecca Siegel, senior scientific director at the American Cancer Society and lead author of the report, said in a statement. “The trend toward more advanced disease in people of all ages is also surprising and should motivate everyone 45 and older to get screened.”
Colorectal cancer rates rising sharply among Gen X and millennials
The overall annual incidence rate of colon cancer has decreased by 46 percent, from 66.2 per 100,000 people at its peak in 1985 to 35.7 per 100,000 people in 2019. Death rates have also dropped 57 percent in the past 50 years, according to the report. Experts say the decrease in colorectal cancer cases is largely because of a drop in smoking and the wide adoption of screening for colorectal cancer in Americans age 50 or older.
But the report, based on the latest available data available through 2019, show the gains against the disease are limited to people 65 and older. Here are some of the findings:
- Incidence rates have increased by 2 percent per year in people younger than 50.
- More people under 50 are dying from the disease. Since 2004, death rates in this age group have increased by about 1 percent annually.
- More patients overall are being diagnosed with regional or distant disease, which means it has spread beyond the colon to nearby or distant lymph nodes, tissues or organs. The incidence of regional stage and distant stage disease has increased by about 3 percent per year in people younger than 50, while rates have stabilized in people age 65 and older after a decade of steep decline.
- Overall men are at higher risk than women. The incidence rate of colorectal cancer was 41.5 per 100,000 in men compared with 31.2 in women. The reason is probably because of differences in risk factors such as an unhealthy diet, a history of smoking and excess body weight, the report said.
- The disease disproportionately affects people of color. Incidence rates are highest in Indigenous Alaskans, (88.5 per 100,000), Native Americans (46 per 100,000) and Blacks (41.7 per 100,000) By comparison, the incidence rate in Whites is 35.7 per 100,000.
Oberstein said there’s “very little understanding” as to why cases of colorectal cancer are on the rise in younger age groups. But other developed countries are seeing a similar trend.
Colorectal cancer is the second most common cause of cancer death in the United States. Smoking, eating processed meats, obesity and a sedentary lifestyle are all risk factors for the disease.
Arif Kamal, the chief patient officer for the American Cancer Society, said one concern is that many people aged 45 to 49 aren’t getting colonoscopy screening even though they are now eligible.
“There’s a clear relationship” between the rate of colonoscopies and the subsequent risk of getting cancer, he said. “The screening is also the therapy. If we see a precancerous polyp, we remove it.”
Kamal said there’s also some concern that people in their 40s and 50s may have less healthful lifestyles, including eating more processed foods and less fiber, than previous generations.
“As obesity rates continue to rise in the United States, we have to identify colorectal cancer as an obesity-related cancer the same way we did when we started to think about lung cancer being a smoking-related cancer,” Kamal said. “It will help people see that one thing leads to another.” Written By: Teddy Amenabar
At CyberKnife Miami we treat colorectal cancer and colon cancer that has spread, which is known as metastatic cancer.
In fact metastatic cancer is the kind of cancer we treat most often at CyberKnife Miami with great success and in a lot less time. Usually, it only takes one to five treatments, compared to 10 to 25 treatments with traditional radiation therapy.
Metastatic cancer is a cancer that has spread from the original (primary) site to another place in the body.
CyberKnife, also known as stereotactic body radiation therapy (SBRT), has emerged as an excellent treatment option for those patients who are not surgical candidates, have failed chemotherapy treatment, or have run the course of treatments and been told there’s nothing left to do.
CyberKnife’s robotic arm and missile-guided image technology allows us to achieve a high level of accuracy by pinpointing a tumor’s exact location throughout the treatment, resulting in successful outcomes.
The sophisticated software uses X-ray images taken constantly during treatment to allow us to precisely deliver radiation to the tumor while minimizing damage to the surrounding healthy tissue and critical structures.
The CyberKnife system can continuously pinpoint and follow a tumor’s exact location as the patient breathes normally. This enables the CyberKnife to zero in on the moving tumor and focus multiple radiation beams from many different angles attacking the tumor. Standard radiation therapy can’t do that.
Each treatment typically lasts 30 to 60 minutes and is performed on an outpatient basis. If tumors come back, we often can treat them again.
The CyberKnife treatment is completely pain free. Patients dress comfortably in their own clothes and can bring music to listen to during treatment. Nothing will be required of the patient, except to relax. In fact, patients often sleep through the treatment.
There are generally only minimal side effects, if any, from CyberKnife treatments, which may include mild nausea and fatigue.
After completing the CyberKnife treatment, patients will schedule follow-up appointments.
Keep in mind tumors will not suddenly disappear. In fact, it could take several weeks or longer to determine the effectiveness of the CyberKnife treatment.
Response to treatment varies from patient to patient. Clinical experience has shown that most patients respond very well.
The number of treatments required depend on how many tumors are present and if they are in close proximity to each other. Research continues to demonstrate a 90 percent control rate for certain types of metastatic cancers treated with CyberKnife.
If you have metastatic cancer, it’s critical to understand your treatment options. To find out if you’re a candidate for life-saving CyberKnife radiosurgery, call the CyberKnife Center of Miami at (800) 204-0455.